Artificial intelligence (AI) has long promised to transform the life sciences, but today, we stand at a critical juncture where this potential is rapidly becoming a reality.
UK psychedelic medicines developer Beckley Psytech has said its candidate for treatment-resistant depression has enhanced the effect of standard antidepressants in a phase 2 trial.
